Atlas Trials

A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

Clinical trial NCT06156527 · RECRUITING

Trial details

NCT number
NCT06156527
Sponsor
National Cancer Center, Korea
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Lazertinib
Start date
2023-09-05
Primary completion
2026-09-05
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.